Osi Eyetech

Mr. Atieh, Executive Vice President and Chief Financial Officer, had previously served as Chair of the OSI Audit Committee and was an outside director of OSI until he took up his current appointment in May 2005. Mr. Atieh had been a director of the corporation since June 2003. Mr. Atieh was recently Group President of Dendrite International and was previously Senior Vice President and Chief Financial Officer at Dendrite. Having started his career as an audit manager at Arthur Young & Company (now Ernst & Young), Mr. Atieh joined Merck and Company and held a number of senior positions from 1981-1994 including Director of Accounting, Director of Investor Relations, Vice President Government Relations, Treasurer, and Vice President of Public Affairs. Mr. Atieh then moved to the Merck-Medco Division of Merck, where he held a number of positions including Senior Vice President of Sales and Business Development. Mr. Atieh subsequently served as Vice President and General Manager of Merck's Medicare business initiative in their U.S. Human Health Division.

Dr. Gibson, is the Chief Scientific Officer of OSI Pharmaceuticals.. In this role he serves as the scientific expert on the Executive Management Committee providing both technical and strategic advice. He works closely with the oncology and diabetes teams heads to identify opportunities for research collaboration between the two areas of focus and with the business development teams to optimize our business development strategies. Dr. Gibson is also responsible for advocating OSI's science to the investment community, as well as continuing to manage the core research activities in the company. Dr. Gibson has also served as Vice President of Research (2002 - 2005) and Vice President of U.S. Research (2002) at OSI Pharmaceuticals. Dr. Gibson began his career with OSI in January 2001 as Senior Director, Cancer Discovery. Dr. Gibson's experiences, prior to joining OSI, include serving as the Director for Cancer Research, Department of Cancer and Osteoporosis at Bayer Corporation; Senior Research Investigator at Pfizer Inc. during which he played an integral role in the Pfizer/OSI cancer collaboration; Associate Professor, School of Pharmacy and Comprehensive Cancer Center University of Southern California; and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. During his career Dr. Gibson has served on the Experimental Therapeutics Study Section of the National Cancer Institute, has been actively involved with the American Association of Cancer Research and is Past President of the British Pharmaceuticals Students Association.

Mr. Leung is currently President of OSI Oncology at OSI Pharmaceuticals, a leading biotechnology company based in Melville, NY. The mission of OSI Oncology is to shape medicine and change lives by discovering, developing and commercializing novel, molecular-targeted therapy for treating cancer. Mr. Leung leads the entire oncology business unit, including Research, Development, Medical Affairs, Sales and Marketing. Prior to joining OSI, Mr. Leung was Group VP, Global Prescription Business at Pharmacia and was a member of the CEO’s Operating Committee. He headed up Pharmacia’s Oncology Franchise with business and medical affairs operations in over 80 countries. Mr. Leung also oversaw all the oncology R&D projects and portfolio strategies as the co-chair of the Oncology Development Committee. During his 4-year tenure at Pharmacia, which ended with the acquisition by Pfizer, he doubled the size of the oncology business to $1.3 billion in revenues, building it into one of the then largest oncology therapeutic companies in the world. He orchestrated two new product launches and helped build one of the strongest oncology pipeline in the industry through acquisition and in-licensing. Mr. Leung began his career in the pharmaceutical industry at Eastman Pharmaceuticals/Sterling Drug Inc., a division of Eastman Kodak Company, where he gained worldwide business development experience. He then had a distinguished career at Bristol-Myers Squibb where he launched and led the growth of multiple pharmaceutical products in oncology and a variety of primary care and specialty therapeutic areas. Mr. Leung is a pharmacist, trained at the University of Texas at Austin where he earned his pharmacy degree with High Honors. Following some years of practice in the hospital environment, Mr. Leung earned his M.S. degree at the University of Wisconsin-Madison with concentration in pharmaceutical marketing. As a member of the National Cancer Institute Clinical Trial Advisory Committee (NCI CTAC), Mr. Leung serves as an advisor to the NCI Director. He is an active member and a member of the Nominating Committee of C-Change (www.cchangetogether.org), a national initiative chaired by former President George Bush and Mrs. Barbara Bush with the goal of reducing cancer mortality and incidence in the United States. Also, he is the founding chairman of the Life Sciences Consortium, a new initiative of the CEO Roundtable on Cancer (www.ceoroundtableoncancer.org). In this role, he leads an industry-wide effort to facilitate cross-company and cross-sector collaboration and to help expedite oncology drug discovery and development. Mr. Leung is a distinguished speaker on healthcare/industry issues and has lectured at major universities.

Ms. Wood is the Senior Vice President, General Counsel and Secretary at OSI. Before joining OSI in 2001, Ms. Wood was a partner in the Corporate Department of the New York office of Squadron Ellenoff Plesent & Sheinfeld LLP (now Hogan and Hartson LLP) where she began her legal career in 1987. Her areas of expertise encompass mergers and acquisitions, complex licensing and collaboration agreements and transactions, private and public securities offerings, venture capital investments and the formation of joint ventures and partnerships. Ms. Wood holds a Bachelor of Arts degree in classics and economics from Connecticut College and a J.D. from Columbia Law School in New York where she was a Harlan Fiske Stone Scholar.

Dr. Franklin is a board-certified ophthalmologist and practicing vitreoretinal surgeon. Dr. Franklin has been actively engaged in clinical research for many years now and has been an investigator for Novartis, Alcon, QLT and Genaera. He is also a published research academician and serves as an advisor to some of the principal companies in the eye disease field (e.g., Novartis and Eyetech Pharmaceuticals). Dr. Franklin was RFE Pharma LLC's co-founder and his research includes work on the lead clinical candidate drug which is being in-licensed for further clinical development. Dr. Franklin received his PhD at Vanderbilt University in molecular physiology related cell type specific development of the pancreatic islet. He completed a residency in ophthalmology at Saint Louis University, and fellowship in vitreoretinal diseases and surgery at University of Iowa where he was a Heed-Knapp fellow. Initial academic work during Dr. Franklin's fellowship was awarded as best research project by a resident or fellow at the 1999 Association of University Professors of Ophthalmology.

Array

Dr. Goddard was appointed Chief Executive Officer of OSI in October 1998. He served as the Company’s President from September 1997 to September 2000; Executive Vice President and Chief Operating Officer from September 1996 to September 1997; Vice President, Research Operations from April 1995 to September 1996; Vice President, Research Operations, Pharmaceutical Division from December 1993 to April 1995; Director, Pharmaceutical Operations from April 1993 to December 1993; Director, Drug Discovery from April 1992 to April 1993; and Program Manager, Drug Discovery from April 1991 to April 1992. Dr. Goddard joined the Corporation as a scientist in January 1989. Dr. Goddard also served as Chairman of the Board from 2000–2002. Dr. Goddard has been a director of the company since October 1998. Dr. Colin Goddard has led the transition of OSI from a technology platform services company into today’s profitable fully integrated biopharmaceutical organization. Dr. Goddard’s leadership and vision were instrumental in the approval and launch of the Company’s flagship product Tarceva® (erlotinib). Dr. Goddard has also led the Company’s corporate development, acquisition and financing efforts in recent years, completing multiple major acquisitions and divestitures and raising over $1.2 billion in capital. Dr. Goddard is active in many organizations which promote the advancement of cancer treatment and awareness, science education and the biotechnology industry. He serves on the board of directors of Zelos Therapeutics, Inc, BIO (the Biotechnology Industry Organization) and Gilda's Club of New York, a cancer charitable organization. Dr. Goddard is a member of the CEO Roundtable on Cancer and the American Association of Cancer Research. Before joining the Corporation, Dr. Goddard spent four years at the National Cancer Institute in Bethesda, Maryland. Dr. Goddard trained as a cancer pharmacologist in Birmingham, U.K. and received his Ph.D. from the University of Aston, Birmingham, U.K. in September 1985. He was honored as a D.Sc. from the State University of New York in 2003 and Hofstra University in 2005.

Dr. Weber has a special interest in Retinopathy of Prematurity and has participated in National Institute of Health funded multicenter studies including ETROP (Early Treatment of Retinopathy) and STOP-ROP (Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity). She served on the Executive Committee and the Outcomes Committee for STOP-ROP. Dr. Weber has additionally been involved in national studies for diabetes, AIDS and macular degeneration. She is an Assistant Professor at SUNY Stony Brook. Currently, she is involved in LEVEL which is a multicenter study sponsored by Pfizer and OSI/Eyetech looking at the role of induction maintenance in wet macular degeneration. She is a consultant for OSI/Eyetech, Pfizer, Estee Lauder and Talia Technology.